Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Parabilis Medicines Inc (PBLS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$30.36+3.79%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PBLS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advance zolucatetide clinical development across multiple indications | Parabilis Medicines is advancing its lead drug, zolucatetide, across multiple cancer indications. | Intact | failure to progress in clinical trials or regulatory submissions | Qualitative progress: Phase III path + new FAP study vs target Recent news confirms Phase III path for desmoid tumors and start of FAP dose-ranging study, indicating continued multi-indication development. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Review the published break conditions above; missing evidence is not proof of success.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The long-term thesis remains insufficiently clear because the available financial history is limited, and confidence in the overall evidence is low.
The evidence does not provide a valuation measure or a clear account of what market expectations already assume, so whether PBLS is cheap or expensive versus peers cannot be assessed. No fragility gates fired, but that alone does not establish that expectations are modest.
In the near term, the company is likely to remain focused on clinical development and pipeline expansion, with minimal revenue and substantial operating losses reported in 2026-Q2. Recent earnings misses and an elevated next-quarter miss risk add uncertainty; management priorities and leadership changes are consistent with an early clinical-stage business, but their outcomes are not yet established.
Over the multi-year view, the thesis hinges on progress advancing zolucatetide across indications and building the Helicon pipeline beyond it. Near-term sector signals are mixed: strong results and guidance from healthcare bellwethers could support the sector backdrop, while weaker employment data or bellwether misses could weaken it.
PBLS remains an uncertain, early-stage clinical development story, with limited revenue, ongoing losses, and no clear valuation or expectations evidence in this snapshot. The 1-3 year thesis depends on clinical and pipeline progress, while near-term earnings and sector risks remain meaningful. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in a supplied disclosure. Management reported: “His unparalleled experience guiding innovative medicines from clinical development and global approval through subsequent product adoption and medical affairs will be tremendously valuable to Parabilis as we continue to advance zolucatetide across multiple indications and build our broader pipeline of Helicon TM therapeutics.” Revenue was $0.148 million in 2026-Q2.
Strengthen leadership with experienced oncology drug developer | A supporting condition in Parabilis Medicines Inc's published investment case. The stated target is qualitative. | Intact | leadership changes that do not align with strategic goals | Qualitative: Leadership aligned with strategic goals News confirms Craig Tendler, a former J&J oncology executive, joined the board in August 2026, enhancing strategic alignment. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in a supplied disclosure. Management reported: ““We are delighted to welcome Craig to the Parabilis Board of Directors,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO and President of Parabilis Medicines.” Net income was $-52.463 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Expand Helicon-based pipeline beyond zolucatetide | A supporting condition in Parabilis Medicines Inc's published investment case. The stated target is qualitative. | Improving | inability to develop new therapeutics or secure funding | Qualitative: 3 pipeline advancements (FAP, Desmoid, Phase III path) vs target of expansion Company initiated FAP dose-ranging study, reported desmoid Phase 1/2 data, and outlined Phase III path for zolucatetide. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in a supplied disclosure. Management reported: “His unparalleled experience guiding innovative medicines from clinical development and global approval through subsequent product adoption and medical affairs will be tremendously valuable to Parabilis as we continue to advance zolucatetide across multiple indications and build our broader pipeline of Helicon TM therapeutics.” Operating income was $-50.886 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.60 → $-1.78 · observed estimates
$0.00B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-09-07 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-08 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-09 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-10 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-11 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-12 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-13 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-14 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-15 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-16 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-17 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-18 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-19 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-20 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-21 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-22 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-23 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-24 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-25 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-26 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-27 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-28 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-29 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-09-30 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-10-01 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-10-02 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-10-03 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-10-04 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-10-05 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-10-06 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-10-07 | $-1.60 | $3,333,330 | 2 / 3 |
| 2026-10-08 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-09 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-10 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-11 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-12 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-13 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-14 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-15 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-16 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-17 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-18 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-19 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-20 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-21 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-22 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-23 | $-2.00 | $3,333,330 | 2 / 3 |
| 2026-10-24 | $-2.00 | $4,750,000 | 2 / 4 |
| 2026-10-25 | $-1.78 | $9,000,000 | 3 / 3 |
| 2026-10-26 | $-1.78 | $9,000,000 | 3 / 3 |
| 2026-10-27 | $-1.78 | $9,000,000 | 3 / 3 |
| 2026-10-28 | $-1.78 | $9,000,000 | 3 / 3 |
| 2026-10-29 | $-1.78 | $9,000,000 | 3 / 3 |
| 2026-10-30 | $-1.78 | $9,000,000 | 3 / 3 |
| 2026-10-31 | $-1.78 | $9,000,000 | 3 / 3 |
| 2026-11-01 | $-1.78 | $9,000,000 | 3 / 3 |
| 2026-11-02 | $-1.78 | $9,000,000 | 3 / 3 |
| 2026-11-03 | $-1.78 | $9,000,000 | 3 / 3 |
| 2026-11-04 | $-1.78 | $9,000,000 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The available assessments flag no unresolved thesis condition. The next results still need to support the ongoing thesis conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.